Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply
Prif Awduron: | Jr, W, Robinson, BG, Gagel, R, Dralle, H, Fagin, J, Santoro, M, Baudin, E, Elisei, R, Jarzab, B, Vasselli, JR, Read, J, Langmuir, P, Ryan, A, Schlumberger, M |
---|---|
Fformat: | Journal article |
Cyhoeddwyd: |
2012
|
Eitemau Tebyg
-
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
gan: Wells, SA, et al.
Cyhoeddwyd: (2012) -
Reply to J.-F. Chatal et al.
gan: Wells Jr, SA, et al.
Cyhoeddwyd: (2012) -
Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
gan: Nils Degrauwe, et al.
Cyhoeddwyd: (2012-06-01) -
Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
gan: Hari Deshpande, et al.
Cyhoeddwyd: (2011-01-01) -
Calcitonin receptor expression in medullary thyroid carcinoma
gan: Virginia Cappagli, et al.
Cyhoeddwyd: (2017-09-01)